Abstract
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1812)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have